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1. Introduction  
Hepatic steatosis affects 20% to 30% of the general adult population in affluent countries. 
Metabolic syndrome and its components—type 2 diabetes mellitus and central obesity—
lead to the development of nonalcoholic fatty liver disease (NAFLD), in part due to insulin 
resistance, apoptosis and altered adipokine and cytokine pathways. Indeed, NAFLD is now 
considered the hepatic manifestation of metabolic syndrome. Globally, NAFLD is a common 
cause of chronic liver disease and, as the obesity epidemic continues, the prevalence of 
NAFLD is anticipated to increase. Non Alcoholic Fatty Disease (NAFLD) encompasses a 
histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis 
(NASH), the latter characterized by steatosis plus necroinflammation. NASH can have 
different stages of fibrosis ranging from absent (stage F0) to cirrhosis (stage F4). Currently, 
the technique of choice for determining hepatic fat deposition and the stage of fibrosis is 
liver biopsy. However, it is an invasive procedure and its use is limited. It may also be 
subject to sampling error. Non-invasive techniques such as ultrasound, computerized 
tomography (CT), magnetic resonance imaging (MRI) and proton magnetic resonance 
spectroscopy (1H MRS) can detect hepatic steatosis, but currently cannot distinguish 
between simple steatosis and steatohepatitis, or stage the degree of fibrosis accurately. Four 
new non-invasive methods received independent validation to assess NASH diagnosis 
(serologic tests) or to stage advanced fibrosis (blood tests, magnetic resonance elastography 
(MRE) and vibration controlled transient elastography (VCTE)).   
The chapter is organized as follows: section 2 describes natural history of NAFLD and 
NASH. The epidemiology is detailed section 3 and the risk factors in section 4. Than the 
limitations of liver biopsy are explained section 5; section 6 contains a description of non 
invasive tools clinically used or at the contrary new development not yet clinically 
evaluated. Advantages and limitations of these devices are detailed. Their applications in 
NAFLD diseases are described. Eventually, discussion and conclusion are drawn in 
section 6 and section 7, respectively. 
2. Natural history: NASH and NAFLD 
Ludwig et al. about 30 years ago described a liver disease that resembled alcoholic hepatitis 
in its histopathologic features but without a history of significant alcohol consumption 
(Ludwig et al. 1980). Since then, literature about non-alcoholic fatty liver disease (NAFLD) 
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has expanded exponentially in attempts to understand its pathophysiology and treat the 
condition. 
The term NAFLD is used to describe a condition of fat accumulation in the liver in the 
absence of excessive alcohol consumption and any other specific causes of hepatic steatosis 
(Ludwig et al. 1980; Bedogni et al. 2006). In the majority of the cases, NAFLD is of primary 
origin and its etiology is not yet completely understood, even if it is strictly related to the 
presence of insulin resistance, and thus frequently occurs as the initial part of the metabolic 
syndrome, and accompanies obesity, type 2 diabetes and dyslipidaemia.  
NAFLD is a chronic liver condition that spans a spectrum of abnormalities ranging from 
simple hepatic steatosis to a predominantly lobular necroinflammation, with or without 
centrilobular fibrosis (termed non-alcoholic steatohepatitis or NASH), which can eventually 
lead to cirrhosis and its associated complications. Around 30% of NAFLD may progress to 
NASH (Farrell & Larter 2006). At the time of diagnosis, the presence of severe fibrosis in 
liver biopsies in patients with NASH has been noted in 15 to 50% of patients and 7% to 26% 
with cirrhosis (Angulo & Lindor 2002). Undiagnosed NASH is the most likely cause for 
cryptogenic cirrhosis (Bugianesi et al. 2002). Hepatocellular carcinoma is also a recognized 
complication of fatty liver disease and emerging evidence suggests that cardiovascular 
disease may also be more common. 
A first phase is responsible for the accumulation of fatty acids in hepatocytes, which 
weakens the adaptive phase hepatocytes and makes them more susceptible to attacks. The 
second phase, lipid peroxidation secondary to oxidative stress, is ultimately responsible for 
cellular damage and the appearance of liver fibrosis.  
In fact, the mechanisms and causes of the initial lesions of steatosis are less known. It is 
recognized that insulin resistance plays a central role in pathogenesis, occurring probably in 
a favorable genetic background. Adipocyte-related factors (leptin, resistin, adiponectin), 
particularly from the visceral fat, have been implicated in causing insulin resistance and 
fatty lesions. The existence of genetic factors predisposing to the development of these 
lesions has also been suggested (mitochondrial abnormalities, genetic polymorphism of 
inflammatory cytokine synthesis).  
3. Epidemiology  
Epidemiological studies can be separated into two categories: selected population studies 
and general screening population studies. The studies using highly selected populations 
suffer from bias but they have high specificity because histology was used to diagnose 
presence of NAFLD and its severity. The general population screening studies provides 
more representative prevalence rates but cannot identify the type of NAFLD because of the 
limitations of their diagnostic technique (Farrell et al. 2005).   
3.1 General screening population studies 
NAFLD is related to modern lifestyle and with expanded clinical importance because of the 
rising incidence of type 2 diabetes mellitus and obesity. In fact NAFLD  affects 20-25% of the 
general population (Bedogni et al. 2006; Nomura et al. 1988) and 20-30% in North America and 
western countries (Angulo & Lindor 2002; Williams 2006), thus it is becoming  one of the 
commonest liver disease worldwide .  NAFLD continues to rise and affects about 30% of the 
adult population in the US now have NAFLD and 3-6 % have NASH (Torres & Harrison 2008).  
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In China, with the increasing pandemic of obesity, the prevalence of NAFLD has 
approximately doubled in the past decade. Among more affluent regions of China, the 
community prevalence of NAFLD is about 15% (Machann et al. 2006), the community 
prevalence of NAFLD in India varies from 5%  to 28%, and varies from 9 to 30% in Japan 
(Amarapurkar et al. 2007). 
The frequency of hepatic steatosis varied significantly with ethnicity (45% in Hispanics; 33% in 
whites; 24% in blacks), the higher prevalence of hepatic steatosis in Hispanics was due to the 
higher prevalence of obesity and insulin resistance in this ethnic group (Browning et al. 2004). 
3.2 Selected study population  
3.2.1 Obese  
NAFLD occurs in the majority of subjects with severe obesity, NAFLD was present in 55-
90% of severely obese patients while NASH occurred in 37% (Farrell & Larter 2006; 
Machado et al. 2006) and 25% has fibrosis (Gholam et al. 2007). 
3.2.2 Children 
NAFLD is the commonest cause of paediatric chronic liver disease in North America (Patton 
et al. 2010), NAFLD was observed in 10% of children in the USA (Adams) and when 
population of obese children are analyzed, NAFLD was found in 40% (Pacifico et al. 2010).  
3.2.3 Healthy young adults 
Nonalcoholic steatosis was discovered in 20% of healthy young adults who are evaluated 
for possible right lobe donor hepatectomy transplantation in adult-to-adult living donor 
transplantation (Marcos et al. 2000)  
3.2.4 Patients who had random deaths  
The liver of subjects died in airplane crashes or traffic accidents  showed prevalence of 16% 
and 24% for NAFLD and  2.1% -2.4% for NASH  (Hilden et al. 1977; Ground 1982).  
All these are strictly selected populations, which do not reflect the true prevalence. 
4. Risk factors 
Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and insulin resistance; it 
is considered the hepatic manifestation of metabolic syndrome. The metabolic syndrome is 
defined by the presence of 3 or more of the following criteriasummarized in Table 1: 
elevated waist circumference, high fasting glucose, hypertension, elevated triglycerides and 
decreased high density lipoprotein concentration. Features of the metabolic syndrome, 
Insulin resistances and systemic hypertension are independently associated with advanced 
forms of NAFLD. NASH is associated with obesity, diabetes mellitus and dyslipidemia.  
Predictors of NASH are: a raised index of insulin resistance(odds ratio OR = 9.3, Cl=3.4 –26, 
systemic hypertension (OR = 5.2, Cl =2.0–13.5), and raised alanine aminotransferase (OR 8.6, 
Cl = 3.1–23.5) (Dixon et al. 2001). The insulin resistance is the strongest predictor of 
NASH(Bugianesi et al. 2002).  
Only a fraction of patient with simple steatosis will progress into the more severe NASH. 
This implies that other factors metabolic, environmental and genetic variables participate in 
the pathogenesis of the disease.  
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Measure  Abnormal level 
Elevated waist circumference Population- and country specific  
definitions   
Elevated triglycerides (drug treatment for 
elevated triglycerides is an alternate indicator) 
≥ 150 mg/dL (1.7 mmol/L) 
Reduced HDL-cholesterol (drug treatment for  
reduced HDL-cholesterol an alternate indicator) 
In Males: < 40 mg /dL (1.0 mmol/L) 
In Females :  < 50 mg/dl (1.3 mmol/L) 
Elevated blood pressure (antihypertensive drug 
treatment in a patient  with history of 
hypertension in a alternate indicator)  
Systolic ≥ 130 and/or diastolic ≥ 
85mmHg 
Elevated fasting glucose (drug  treatment is 
alternate indicator)  
≥ 100 mg/dL 
Table 1. Criteria for Clinical Diagnosis of the Metabolic Syndrome from (Alberti et al. 2009). 
5. Liver biopsy: a limited gold standard  
In the precedent section, we saw that typical histologic features of NASH primarily include 
macrovesicular steatosis, a mixed lobular inflammation, and hepatocellular ballooning. 
Thus, for the diagnosis of NASH to be established, a liver biopsy is still required and 
therefore remains the gold standard. Only information from biopsy allows grading and 
staging of the disease. 
5.1 Non-alcoholic fatty liver disease: an histological diagnosis 
Non-alcoholic fatty liver disease (NAFLD) is a complex metabolic liver disease. The clinical 
spectrum of NAFLD ranges from benign steatosis to steatohepatitis (Farrell 2004), named 
NASH (non-alcoholic steatosis hepatitis). NASH defines a sub-group of NAFLD patients 
where steatosis coexist with liver-cell injury and inflammation (Ratziu et al. 2009). NASH is 
a progressive form of liver injury that may lead to liver fibrosis which can result in cirrhosis, 
liver failure and hepatocellular carcinoma (Farrell 2004; Ratziu et al. 2009). 
The diagnosis of NAFLD is clinicopathological. NAFLD or NASH can be defined as 
significant steatosis or steatohepatitis not resulting from alcohol, drugs, toxins, infectious 
agents or other exogenous causes (Farrell 2004). NASH was first described in 1980 by 
Ludwig et al. (Ludwig et al. 1980) who described a series of patients with chronic liver 
disease and no history of significant alcohol intake in whom the liver histology was similar 
to patients with alcoholic liver disease.   
The diagnosis of NAFLD is usually suspected in patients with asymptomatic and persistent 
elevation of aminotransferase, radiological finding of fatty liver and unexplained persistent 
hepatomegaly (Angulo & Lindor 2002). However the elevation of liver enzyme has a poor 
predictive value (Angulo & Lindor 2002; Clark et al. 2002) and no clinical or biochemical 
abnormality permit an accurate diagnosis of NAFLD (Angulo & Lindor 2002). Liver imaging 
is useful to determine the presence of fatty infiltration but cannot determine the presence 
and severity of liver damage (Angulo & Lindor 2002).  
A liver biopsy is the gold standard to diagnose NAFLD/NASH (Nugent & Younossi 2007) 
and determine the stage of hepatic fibrosis (Nugent & Younossi 2007). Liver biopsy is the 
only way to establish definite diagnosis of NASH (Nugent & Younossi 2007) and is the only 
technique which can distinguish simple steatosis from steatohepatitis (Farrell 2004). 
A liver biopsy can assess all liver features associated with NAFLD e.g. steatosis, 
hepatocellular injury, inflammation, fibrosis, etc. (Angulo & Lindor 2002) and can make the 
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distinction with chronic liver disease from other cause (Ratziu et al. 2009). Liver biopsy 
provides information about the stage of hepatic fibrosis which is the most crucial clinical 
prognostic information.  
However despite all advantages of liver biopsy, its role for NAFLD patients in clinical 
practice remains controversial (Nugent & Younossi 2007).  
5.2 When to consider a liver biopsy for NAFLD patients 
A liver biopsy is essential for the diagnosis and staging of NAFLD. However given its 
invasiveness, its potential severe complication and the lack of treatment for NAFLD patients 
(Nugent & Younossi 2007), the decision for the hepatologist to refer to liver biopsy might be 
difficult. Furthermore, NAFLD patients are asymptomatic and are reluctant to undergo a 
liver biopsy (Nugent & Younossi 2007). 
Decision for the hepatologist to refer to a liver biopsy is made on individual basis (Ratziu et 
al. 2009; Nugent & Younossi 2007). According the 2010 position statement on 
NAFLD/NASH of the European Association for the Study of the Liver (EASL) (Ratziu et al. 
2009), a liver biopsy should be performed in patients: 
• with disorders of the metabolic syndrome for whom non-invasive methods suggest 
advanced fibrosis or yield discordant results, 
• with chronic liver disease not related to NAFLD and evidence of metabolic risk factors, 
insulin-resistance and steatosis at ultrasound, 
•  undergoing bariatric surgery and cholecystectomy. 
Furthermore, in patients with disorders of the metabolic syndrome with both increased 
alanine transferase and steatosis at ultrasound, liver biopsy could be the first-line procedure 
until non-invasive methods becomes extensively and independently validated (Ratziu et al. 
2009). 
5.3 NAFLD liver histology 
5.3.1 Histological liver lesions associated with NAFLD 
The zonal location of liver lesions is an important feature for histological evaluation. Briefly, 
liver is histologically divided into lobules which take the shape of a hexagon (Dancygier 
2010), as represented in Figure 1. 
 
 
Fig. 1. Liver lobule organization. 
At the centre of the lobule is the central vein. At the periphery of the lobular are portal tract. 
The portal tract is an island of connective tissue containing branches of the portal vein, 
hepatic artery and bile duct. Portal vein and hepatic artery empty into the sinusoid, from 
which blood flows to the central vein.  
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The liver lobule can be divided into three zones: the periportal zone which encircles the 
portal tract, the centrolobular zone which encircles the central vein and the zone in between 
named midlobular zone.   
In NAFLD/NASH, steatosis, necroinflammation, Mallory’s hyaline and fibrosis are typically 
concentrated in the centrolobular zone (Angulo & Lindor 2002). 
5.3.1.1 Steatosis 
Steatosis is characterized by the accumulation of fat droplets in the liver. Steatosis is 
necessary for the diagnosis of NAFLD except for patients with cirrhosis for whom steatosis 
can be absent. The minimal threshold to diagnose steatosis is 5% of hepatocytes containing 
fat droplets.  
Steatosis in NAFLD patients is mainly macrovesicular (Farrell 2004) which means that fat is 
a single droplet that fill in the hepatocyte and displace its nucleus at the periphery of the 
cell. Sometimes microvesicular steatosis can also be seen but in a smaller proportion and in 
that case, the hepatocytes contain a large number of tinier droplets surrounding the central 
nucleus (Farrell 2004).  
In NAFLD early or mild steatosis is seen in centrolobular zone (Farrell 2004). 
Simple steatosis is a reversible condition in a matter of days to weeks (Farrell 2004).    
5.3.1.2 Hepatocyte injuries 
Hepatocyte injuries that frequently occur in NAFLD are: hepatocellular ballooning, liver cell 
death, and Mallory’s hyaline (Farrell 2004).  
Hepatocellular ballooning is a structural manifestation of severe cell injury (Schattner & 
Knobler 2008). Ballooned hepatocytes are enlarged and have a pale cytoplasm as a result of 
fluid retention (Farrell 2004), with a rarefaction of the cytoplasm (Schattner & Knobler 2008). 
Ballooning degeneration is reversible (Farrell 2004) but is likely a form of necrosis (Schattner 
& Knobler 2008). Hepatocellular ballooning is seen most of the time in the centri-lobular 
zone, mixed or adjacent to regions with steatosis (Schattner & Knobler 2008). 
Liver cell death can be seen in the form of necrosis or apoptosis and is not reversible (Farrell 
2004). Apoptotic hepatocytes cells are seen as shrunken cells with densely condensed nuclei 
(Farrell 2004). Necrotic hepatocytes are not usually prominent but mixed inflammatory 
infiltrate can be seen is the site where necrotic hepatocytes have disappeared (Farrell 2004).  
Mallory’s hyaline is seen as a ropy inclusion with the cytoplasm of hepatocytes, especially in 
cells showing ballooning degeneration (Farrell 2004). It develops as a result of an impaired 
proteosomal degradation of cytoplasmic proteins (Schattner & Knobler 2008). 
Other lesions can be seen in NAFLD: glycogenated nuclei, lipogranulomas, Kupffer cells, 
mitochondrial abnormalities, fatty cyst, etc. (Schattner & Knobler 2008; Brunt 2005). 
5.3.1.3 Inflammation 
The hallmark of inflammation in NAFLD is the lobular inflammation (Schattner & Knobler 
2008). Lobular inflammation is characterized by the presence of typically mild mixed 
inflammation, close to ballooned hepatocytes (Schattner & Knobler 2008),  and includes a 
small number of lymphocytes, a small number of macrophages, Kupffer cells, but also a 
small number of polymorphonuclear leukocytes (Brunt 2005). Portal inflammation can also 
be seen in NAFLD (Brunt 2005). 
5.3.1.4 Fibrosis 
In NASH, fibrosis is first seen in the centrilobular zone (Angulo & Lindor 2002; Farrell 2004). 
This fibrosis is characteriscally perisinusoidal (Brunt 2005). This fibrosis can progress portal 
fibrosis, central-portal and portal-portal septum and eventually cirrhosis (Angulo & Lindor 
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2002). Around 20% of NASH patients may progress to cirrhosis (Angulo & Lindor 2002; 
Farrell 2004). In patients with cirrhosis, the features of steatosis and necroinflammatory 
activity may no longer be present (Angulo & Lindor 2002).  
5.3.2 Histological description of NAFLD/NASH 
There is currently no evaluation system massively admitted by experts for the evaluation of 
NAFLD (Angulo & Lindor 2002; Farrell 2004; Nugent & Younossi 2007; Brunt 2007). For 
instance, some authors (Farrell 2004; Brunt et al. 1999) but not all (Farrell 2004; Diehl 2002) 
consider ballooning as an absolute requisite for the diagnosis of NASH, it can be the same 
for other histological features such as Mallory’s hyaline (Brunt 2005). 
The early description of NAFLD described four subtypes: fatty liver, fatty hepatitis, fatty 
fibrosis and fatty cirrhosis (Adler & Schaffner 1979).  
Ludwid et al. characterized NASH specimen by the presence of steatosis, necrosis, lobular 
inflammation and in most specimens Mallory’s hyaline and fibrosis (Ludwig et al. 1980). 
Matteoni et al. (Matteoni et al. 1999) proposed in 1997 the classification summarized in  
Table 2.  
 
Type of NAFLD Histological description Prognosis 
Type 1 Simple steatosis Begnin 
Type 2 Steatohepatitis : steatosis plus lobular inflammation 
Probably 
begnin 
Type 3 Steatonecrosis: steatosis and ballooning Bad prognosis 
Type 4 
Steatonecrosis  plus fibrosis: steatosis, lobular 
inflammation, ballooning, Mallory’s hyaline and/or 
fibrosis 
Bad prognosis  
Table 2. Types of NAFLD according to (Matteoni et al. 1999). 
Brunt et al. (Brunt et al. 1999) have proposed in 1999 a grading and staging system for 
NASH. This system includes a necroinflammatory grade and a fibrosis score. The 
necroinflammatory grade is a combination of features of steatosis, ballooning and 
inflammation since no single feature can determine activity. The three grades are 
summarized in Table 3. 
 
Grade Histological characteristics 
Grade 1 – mild 
Steatosis: up to 66%. 
Ballooning: mild, occasional 
Lobular inflammation: scattered and mild 
Portal inflammation: absent to mild 
Grade 2 – moderate 
Steatosis: any degree 
Ballooning: moderate, obvious in centrolobular zone 
Lobular inflammation: mild to moderate 
Portal Inflammation: mild to moderate  
Grade 3 – severe 
Steatosis: any degree 
Ballooning: severe, marked in centrilobular zone 
Lobular inflammation: severe 
Portal inflammation: mild to moderate 
Table 3. Necroinflammatory grading system for NASH from (Brunt et al. 1999). 
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In addition, Brunt et al. (Brunt et al. 1999) proposed a staging system for fibrosis in NASH. 
This staging is summarized in Table 4.  
 
Stage Histological description 
0 No fibrosis 
1 Centrilobular perisinusoidal fibrosis 
2 Centrilobular perisinusoidal fibrosis and portal/periportal fibrosis 
3 Bridging fibrosis 
4 Cirrhosis 
Table 4. Staging of fibrosis for NASH, according to (Brunt et al. 1999).  
Eventually, by Kleiner et al. from the NASH clinical research network developed (Kleiner et 
al. 2005) in 2005 an approach for the assessment of NAFLD. This scoring system grade three 
histological features: steatosis, inflammation and ballooning according to standardized 
histological evaluation summarized in Table 5.    
 
Histological feature Histological evaluation Score 




> 66% 3 
No foci 0 
1~2 foci per 200xfield 1 
2-4 foci per 200xfield 2 
Lobular inflammation 
>4 foci per 200xfield 3 
None 0 
Few cells 1 Ballooning 
Many cells/prominent 2 
Table 5. Scoring system for steatosis, lobular inflammation and ballooning for NAFLD 
(Kleiner et al. 2005). 
Then, the score of each feature (steatosis, lobular inflammation and ballooning) are summed 
up to constitute the NAFLD activity score (NAS score) which ranges from 0-8. According to 
the NAS score, the diagnosis of NASH can be made or excluded as described in Table 6.  
 
NAS score Diagnosis 
≤ 2 No NASH 
3-4 Borderline 
≥ 5 NASH 
Table 6. Diagnosis of NASH upon the NAFLD activity score (NAS), according to (Kleiner et 
al. 2005). 
In addition, Kleiner et al. (Kleiner et al. 2005) have proposed a staging system of fibrosis for 
NAFLD patients, which is summarized in Table 7. 
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Stage Histological description 
0 No fibrosis 
1 Perisinusoidal or periportal fibrosis 
1A Mild centrilobular perisinusoidal fibrosis 
1B Moderate centrilobular perisinusoidal fibrosis 
1C Portal/periportal fibrosis 
2 Perisinusoidal and portal/periportal fibrosis 
3 Bridging fibrosis 
4 Cirrhosis 
Table 7. Staging of fibrosis, according to (Kleiner et al. 2005).  
The Kleiner score is very fetching since it provides a standardized approach for diagnosis of 
NASH and this score tend to be widely used, especially for clinical studies of patients with 
NASH. However, despite the practical side of NAS score, it has some limitations and does 
not perfectly correlate with the definite diagnosis of NASH (Brunt et al. 2011).  
5.4 Advantages and drawbacks of liver biopsy 
5.4.1 Advantages 
Despite its limitations, liver biopsy is the only method for: 
• diagnosis : to distinguish simple steatosis from steatohepatitis (Farrell 2004), 
• prognosis: grading and staging of NAFLD. 
5.4.2 Drawbacks 
Liver biopsy is invasive, often painful procedure which can result in severe complications 
(Grant & Neuberger 1999). Its invasiveness implies that it cannot be performed repeatedly to 
monitor NAFLD or NASH after intervention.  
Liver biopsy can only be performed in selected patients, according to the type of liver 
biopsy. The mains liver biopsy procedures are summarized in the next paragraph, together 
with their contraindications and possible complications.  
5.4.3 Type of liver biopsy: procedure, contraindication and complications  
The three main types of liver biopsy are the percutaneous liver biopsy, transjugular liver 
biopsy and laparoscopic liver biopsy (Grant & Neuberger 1999; Bravo et al. 2001). 
Laparoscopic liver biopsy is rarely used (Bravo et al. 2001) and therefore will not be 
described hereafter. Its complications include those of laparoscopy itself (Bravo et al. 2001). 
5.4.3.1 Percutaneous liver biopsy 
Percutaneous liver biopsy is the commonest liver biopsy technique.  
Patients should lie in bed and are monitored for at least six hours after the biopsy (Bravo et 
al. 2001). Patient should be driven home from the hospital and reliable person should stay 
with the patient the night after the biopsy to provide care and transportation if necessary 
(Bravo et al. 2001). Patient should be hospitalized after liver biopsy if there is evidence of 
bleeding, bile leak, pneumothorax (Bravo et al. 2001). 
The contraindication for a percutaneous liver biopsy include: uncooperative patients, 
history of unexplained bleeding, extrahepatic biliary obstruction, bacterial cholangitis, 
abnormal coagulation indexes, cardiac liver, ascite, blood for transfusion unavailable, 
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suspected vascular tumor, suspected cyst in the liver (Grant & Neuberger 1999; Bravo et al. 
2001). 
Most of complications occur within 24 hours after the procedure (Piccinino et al. 1986) and 
sixty percent of complications occur within 2 hours. Commonest complications are pain and 
vasovagal episodes. Major complications are significant haemorrhage, haemobilia, puncture 
of other viscera and pneumothorax (Grant & Neuberger 1999). Mortality rate is around 
0.1‰ (Bravo et al. 2001). The main cause of mortality after liver biopsy in intraperitoneal 
bleeding (Grant & Neuberger 1999).  
5.4.3.2 Transjugular liver biopsy 
Transjugular liver biopsy is recommended for most patients for whom percutaneous liver 
biopsy cannot be performed (Grant & Neuberger 1999) that is with cogulapathy, ascite, 
massive obesity, suspected vascular tumors and in patients for whom percutaneous liver 
biopsy failed (Bravo et al. 2001). 
Procure last around on hour. A catheter is inserted in the right internal transjugular vein 
and guided via fluoroscopy (live X-ray) to the right hepatic vein. A needle biopsy of the 
liver is then performed through the catheter (Bravo et al. 2001). 
Complications occurs in around 1 to 20% of patients and include: abdominal pain, neck 
hematoma, cardiac arrhythmias, fistula from the hepatic artery to the portal vein or biliary 
three and perforation of the liver capsule (Bravo et al. 2001).  Mortality rate is around 0.1% 
to 0.5% (Bravo et al. 2001).   
5.4.4 Sampling, intra/inter observer variability & effect of liver biopsy sample length 
5.4.4.1 Sampling variability 
A limitation of liver biopsy is its sampling variability (Ratziu et al. 2009; Qayyum et al. 
2005). Sampling variability is a relevant limitation of liver biopsy due to the fact that the 
liver biopsy specimen represent only a very limited part of the whole liver (Bravo et al. 2001) 
and that histologic lesions of NAFLD/NASH are likely to have a very unevenly distribution 
in the liver (Brunt 2008), even at a macroscopic level. 
Indeed, in Merriman et al. (Qayyum et al. 2005), 41 subjects underwent intraoperative liver 
biopsies from both right and left lobes. The κ coefficient was assessed and shown: excellent 
agreement for steatosis (κ = 0.88), moderate for fibrosis staging and lobular inflammation (κ 
= 0.53 and κ = 0.32, respectively) and slight for ballooning and portal inflammation (κ = 0.20 
and κ = 0.19, respectively).     
In Ratziu et al. (Ratziu et al. 2009), 2 samples of liver biopsy were successively collected in 51 
patients. The κ reliability test was assessed and shown: substantial agreement for steatosis (κ 
= 0.64), moderate agreement for fibrosis staging and ballooning (κ = 0.47 and κ = 0.45, 
respectively), fair agreement for Mallory’s hyaline (κ = 0.27) and poor agreement for lobular 
inflammation (κ = 0.13).       
The heterogeneous distribution of histological lesions of NAFLD/NASH is particularly 
accentuated for lobular inflammation and ballooning that are key features in NASH diagnosis.  
To avoid as much as possible potential sampling variability error, large specimen are 
required for reliable evaluation of NAFLD patients (Brunt 2007; Vuppalanchi et al. 2009). 
Usually, most of the pathologists recommend a specimen of at least 1.5 cm with at least six 
to eight portal tracts (Bravo et al. 2001), and preferably a specimen of at least 25 mm is 
preferable (Vuppalanchi et al. 2009). 
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5.4.4.2 Intra/inter-observer variability 
Intra/inter-observer variability is an important cause of error when staging and grading 
liver biopsy (Ratziu et al. 2009; Marcellin et al. 2009; El-Badry et al. 2009) which can yield 
poor reproducibility even when performed by experts pathologists (El-Badry et al. 2009).  
In the study by El-Badry et al. (El-Badry et al. 2009), 4 established expert pathologist from 
different institutions worldwide were asked to grade steatosis from 46 NAFLD patients. 
Concomitant computerized morphometric analysis was performed on the same slides. Poor 
agreement was found among pathologists for the evaluation of total steatosis: intra-class 
correlation agreement ICC = 0.57, macrovesicular steatosis ICC = 0.55. Failed agreement was 
found for the evaluation of micro-vesicular steatosis. When compared with computerized 
morphometic analysis, poor agreement was found for 3 pathologists (Spearman rank 
correlation coefficient ρ = 0.22, 0.28 and 0.38) and good agreement was found for one 
pathologist (ρ = 0.82). In addition, features of NASH (lobular and portal inflammation, 
ballooning, Mallory’s hyaline) were assessed by the 4 pathologists as present or absent, as 
well as diagnosis of NASH, and a strong disagreement was found for all parameters 
including the overall diagnosis. Evaluation of NAFLD/NASH is therefore strongly 
observer-dependent and therefore seems weakly reproducible.   
Even when performed by the same operator, variability can be important. Indeed, in Ratziu 
et al. (Ratziu et al. 2009), intra-observer variability was assessed on 50 liver biopsies and 
intra-observer κ reliability test yield to substantial agreement for steatosis (κ = 0.74), 
moderate agreement for ballooning (κ = 0.62), perisinusoidal fibrosis (κ = 0.53), fair 
agreement for Mallory’s hyaline (κ = 0.39) and lobular inflammation (κ = 0.37). Overall 
staging of fibrosis was substantial (κ = 0.69) and grading of NAFLD was moderate (κ = 0.55).  
5.4.4.3 Other cause of variability 
Some other parameters such as tissue fixation and staining methods can also influence the 
evaluation and be a cause of variability in the assessment of NAFLD/NASH (DiDonato & 
Brasaemle 2003; Fukumoto & Fujimoto 2002).   
5.4.4.4 Impact of variability 
Sampling error, intra and inter-observer variability and other causes of variability may 
induce misdiagnosis and substantial staging inaccuracy that might have significant 
implication in the clinical management of NAFLD/NASH patients.      
6. Non invasive tools: how to detect transition between steatosis and 
fibrosis?  
Hepatic steatosis refers to the excessive accumulation of fat within hepatocytes. The most 
common form of steatosis is nonalcoholic fatty liver disease (NAFLD), which comprises a 
wide spectrum of liver damage, ranging from simple steatosis (`fatty liver') to nonalcoholic 
steatohepatitis (NASH), advanced fibrosis, and cirrhosis. Several systems of grading and 
staging of NAFLD have been proposed, but only a few have been validated; these typically 
include the degrees of steatosis, cytological ballooning, infammation, and fibrosis. To 
replace the biopsy, the ideal non invasive tool has to detect and quantify the same 
parameters than biopsy. The most important of a clinical point of view is to detect transition 
between simple steatosis and beginning of hepatitis. This review discusses of a part of 
current non invasive tools used to clinical diagnosis NAFLD and/or NASH and then these 
tools are compared to biopsy efficiency. 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
46 
6.1 The past: non invasive tools currently used in clinical practice 
6.1.1 Ultrasound 
Ultrasound imaging is an established imaging modality in the diagnosis of hepatic steatosis, 
both clinically and in large scale studies. Several grading system have been proposed, 
studied, evaluated for the assessment of steatosis using ultrasound but no consensus has 
been achieved.  
Ultrasound is the commonest technique used in clinical practice to detect fatty infiltration of 
the liver due to its simplicity, low cost, noninvasive nature, and widespread availability 
(Karcaaltincaba 2007). However, accurate quantification of steatosis is not feasible with the 
current technology. The basic principle underlying the sonographic detection of steatosis is 
that the degree of tissue brightness, the so-called echogenicity, directly depends on fat 
composition of the tissue (Quinn et al. 1985). Hence, a fatty liver is hyperechogenic with fine 
and tightly packed echoes and appears brighter on ultrasound examination (`bright liver') 
when compared with the echogenicity of other fat-free internal organs such as the kidneys 
or spleen (Joseph AE, et al.1979, Vaalls et al, 2007, ,Joy D; et al., 2003). The ‘quantification’ of 
steatosis depends on the experience of the operator: mild steatosis is characterized by ‘mild’ 
increase in liver echogenicity. Moderate steatosis can be diagnosed with increased liver 
echogenicity compared to the spleen for example, echogeneicity that obscures visualization 
of hepatic and portal vein wall. However, ultrasonographic evaluation of steatosis does not 
exactly match histopathologic quantification of steatosis. Furthermore, fat is less penetrable 
by ultrasound leading to attenuation of the signal, which causes posterior darkness (i.e., 
acoustic shadowing leading to hypoechogenicity in the far field) and loss of definition of the 
diaphragm and portal and hepatic veins, giving rise to a relatively bland and featureless 
appearance of the liver. It’s the criteria to diagnose steatosis ≥30% (Palmentieri B. et al., 
2006). Evaluation of steatosis in patients with hepatitis can be difficult due to accompanying 
inflammation and fibrosis. Fibrosis may also appear hyperechoic, but most of the time 
fibrosis and fatty infiltration co-exist in cirrhotic patients which is called fatty–fibrotic 
pattern (Joseph AEA, 1991). Still, despite the fact that several attempts have been made to 
generate scoring systems in order to provide better semi-quantitative information on the 
degree of steatosis (Hamaguchi M, 2007,  Mehta SR  2008), ultrasonography remains largely 
a qualitative method for detecting NAFLD rather than a quantitative one for measuring 
liver fat. Several studies have examined the ability of ultrasound in recognizing fatty liver 
among patients suspected of having liver disease, using liver biopsy as the comparison 
standard, and reported sensitivity values between 60 and 94%and specificity values between 
84 and 95%( Joy D. et al, 2003). the sensitivity is 55% when intrahepatic fat content is 10±20% 
and rises to 80% when intrahepatic fat content is greater than 30% (Ryan CK. Et al,  
Hence, its ability to detect longitudinal changes is poor; it has been estimated that even a 
reduction of intrahepatic fat content from 40 to 20% following a successful intervention 
would alter the sonographic appearance of the liver by little, if any ( Fishbein et al., 2005). 
Moreover, both the sensitivity and specificity of ultrasound decrease sharply in morbidly 
obese patients ( Mottin CC. et al. 2004). Technical factors such as transducer frequency and 
instrument settings also affect the sonographic appearance of the liver, and hence the 
performance of ultrasound (Yeh WC et al. 2005, Garra B.S. et al.1887).  
Sonography has the advantages of ease of acquisition, ability to assess the whole liver. The 
drawback are: subjectivity of the operator, no precise quantification, no follow-up of 
progression of the disease, poor agreement of intraobserver reproducibility (0.4-0.51) and 
interobserver (0.58) (Strauss S et al. , 2007).  
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We can conclude that abdominal ultrasound is a moderately specific and sensitive tool for 
diagnosing hepatic steatosis  (> 33 %) but is not predictive for NASH. 
6.1.2 Computed tomography (CT) 
Noncontrast-enhanced computed tomography (CT) is widely used for the evaluation of 
NAFLD, by means of measuring tissue density as a function of radiographic attenuation. 
Tissue fat deposition results in lower attenuation (Kawata R et al., 1984), hence fatty tissues 
are less dense and appear darker than fat-free tissues (Piekarski J et al. 1980). Attenuation 
and density on CT imaging can be objectively measured on the Hounsfield scale. Fibrosis 
does not cause any effect on the attenuation of liver (Joy D et al. 2003). The diagnosis of fatty 
liver by contrast-enhanced CT imaging is more cumbersome, because contrast type and 
injection rate and timing of measurements can significantly influence the optimal liver-to-
spleen attenuation difference for diagnosing NAFLD. Hence, unenhanced hepatic scanning 
remains the optimal CT technique for the detection of fatty liver (Kodama Y et al. 2007). 
Unenhanced CT images are used for qualitative evaluation and spleen is used as the 
reference organ for comparison. Spleen to liver attenuation ratio or difference between 
attenuation of spleen and liver can be used for the evaluation of steatosis. Studies that have 
evaluated CT imaging against liver biopsy have reported that the liver CT attenuation value 
and the ratio of liver-to-spleen CT attenuation values (Longo R et al. 1993, Oliva MR  et al. 
2006) correlate well with the degree of steatosis by histological analysis. Attenuation of 
spleen is approximately 8–10 HU less than the liver in a normal patient. Iwasaki et al. 
suggested cut-off value of 1.1 (spleen to liver attenuation ratio) for exclusion of moderate 
steatosis based on their correlative findings on 194 patients (Iwasaki M et al., 2004). The 
sensitivity and specificity of noncontrast-enhanced CT in the detection of moderate and 
severe hepatic steatosis (intrahepatic fat >30%) have been reported to range between 73% 
and 95%, respectively. However, at lower degrees of steatosis, the diagnostic performance of 
unenhanced C T for the quantitative assessment of intrahepatic fat is not clinically 
acceptable (Park SH et al. 2006) nor is C T able to evaluate hepatic fibrosis. In their study, 
liver/spleen attenuation ratio of 0.8 and difference of 9H between liver and spleen 
attenuation had similar sensitivity. Use of suggested criteria can be helpful in avoiding 
biopsy in moderately steatosic livers (Brancatelli G, 2006). In another study, Limanond et al. 
2004  also concluded that unenhanced CT  quantified the degree of steatosis relatively well 
in liver donor patients, but stated that most of the time liver biopsy is necessary to exclude 
fatty liver, co-existing iron deposition and parenchymal disease.  
It should be noted that radiographic attenuation through the liver is non-uniform due to many 
factors that cannot be measured by CT, such as iron, copper, and glycogen concentrations and 
presence of fibrosis or oedema. For example, up to 40% of patients with NASH may have 
hepatic iron overload (George DK et al. 1998), which would alter hepatic CT attenuation 
independently of intrahepatic fat content. Recently, xenon CT, which is widely used to 
quantify and visualize tissue blood flow, was evaluated for its ability to assess fatty infiltration 
and changes in blood flow throughout the entire liver; it was found that xenon solubility was 
strongly and positively correlated with both grade of steatosis and each 10% range of 
histological fatty infiltration (r value > 0.8) and inversely associated with the liver-to-spleen CT 
attenuation ratio (Kobayashi M et al. 2009). Hence, xenon CT appears to provide a more 
objective measure of the severity of hepatic steatosis than conventional CT. However, the 
major limitation of CT is the exposure of patients to ionizing radiation, which makes 
longitudinal assessment of NAFLD impractical, especially among sensitive populations. 
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6.2 Magnetic resonance imaging (MRI) 
Moderate-to-severe hepatic steatosis can easily be detected on T1-weighted spin-echo MRI 
because liver fat has very high signal intensity (Danet IM et al. 2003). This sequence can be 
obtained with all types of MR scanners with different Tesla power including 0.5, 1, 1.5 and 3 
Tesla. In the presence of steatosis signal drop is observed on out of phase images due to 
phase cancellation of fat and water. However, many other factors contribute to this high 
signal intensity such as haemorrhage, melanin deposition, high protein content, or 
sinusoidal dilatation. The signal intensity is much lower for mild fatty infiltration of the 
liver. Therefore, in clinical practice, the most common MRI modality to evaluate NAFLD is 
chemical-shift imaging, which utilizes the difference in resonance frequency of water 
andlipidhydrogens to differentiate tissues containing only water from those containing both 
water and lipid (Venkataraman S et al. 2002. The spleen is generally used as the internal 
organ of reference for signal loss. For mild degrees of steatosis (intrahepatic fat < 15%), the 
signal of liver on the out-of-phase images appears nearly equal to that of spleen, although 
demonstrating a slightly higher signal on the in-phase images; loss of signal on out-of-phase 
images is progressively more prominent in moderate and severe fatty infiltration. 
Quantification of intrahepatic fat is made possible because of the differences in resonance 
frequencies between fat and water; if the out-of-phase and in-phase images are acquired by 
using constant calibration and other scanner settings, a quantitative fat signal fraction can be 
calculated from the hepatic signal intensities and this can be done pixel by pixel on the 
image to generate a fat signal fraction map. Many limitations of this technique (e.g., time-
demanding, low sensitivity, disturbed image quality due to respiratory and other bodily 
motions, or by magnetic field heterogeneity have been overcome by new methods, such as 
spoiled gradient-echo pulse sequence imaging, fast gradient echo imaging, fat-saturated fast 
spin-echo imaging, and fast spin-echo triple-echo Dixon imaging for example. These 
improved techniques have been shown to accurately quantify the hepatic fat fraction, even 
at low or near-normal levels. Guiu et al . 2009 recently developed a method on a breath-hold 
triple-echo spoiled gradient-echo sequence, which has many asserted advantages such as 
shorter acquisition time, measurement of fat content throughout the liver instead of in one 
or just a few voxels, no spatial misregistration errors, as well as easier and faster processing. 
Generally, the sensitivity and specificity of MRI for the detection of moderate and severe 
steatosis are greater than 80 and 95%, respectively; in addition, MRI has agreater than 85% 
sensitivity and a nearly 100% specificity for mild steatosis (intrahepatic fat 5±10%) (Mazhar 
et al. 2009). It was confirmed by many studies which have reported very good correlations 
between quantitative estimations of hepatic steatosis on MRI compared with liver biopsy 
(Cowin et al. 2008).  
Nevertheless this technique is very expensive, not always available in hospital and does not 
quantify fibrosis. 
6.2.1 Magnetic resonance spectroscopy (MRS) 
Whereas chemical shift MRI enables the identification of steatosis within whole tissues, 
proton MRS facilitates the examination of the resonance frequencies of all hydrogen nuclei 
within a tissue region of interest (localized MRS). Although the absolute differences in 
resonance frequencies between protons in water and fat are quite small (3.5 ppm), they can 
be separated out to form a spectrum on an axis of chemical shift; spectral resolution is 
determined by the strength of the main magnetic field (1.5 Tesla). The intrahepatic fat values 
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obtained by proton MRS are highly reproducible (Machann J et al., 2006) and correlate well 
with histological analysis of liver biopsy samples (Frimel TN et al., 2007). Moreover, the 
potential ability of MRS to monitor the progression of steatohepatitis by assessing saturated 
and unsaturated composition of fatty acyl chains in the liver has been tested in animal 
models, with promising results (Corbin IR, et al. 2009). MRS has been widely used in 
research settings for assessing the prevalence and metabolic concomitants of NAFLD among 
various populations including children as well as in longitudinal studies for evaluating fatty 
liver in response to drug treatments (Belfort R, et al. 2006)  or changes in diet and physical 
activity. 
6.3 The future: non invasive tools recently developed 
6.3.1 Magnetic resonance elastography (MRE) 
MR elastography (MRE) is an emerging technique for quantitatively imaging the mechanical 
properties of tissues. The basic approach is to generate low frequency mechanical waves 
(typically 20 to 200Hz) in the tissues and to use an extremely sensitive phase-contrast MR 
technique to quantify tissues displacements. MRE requires the addition of hardware and 
software to standard MR imaging system and a drumlike acoustic passive driver which is 
positioned against the body wall. The active driver produces acoustic vibrations which are 
transmitted to the passive driver, which then transmits it through  the body and generate 
shear waves in liver. Recorded information is then processed by an inversion algorithm to 
generate quantitative images that depict tissues stiffness. The tissues stiffness expressed in 
kPa is correlated to the amount of fibrosis. Pr Ehman suggests that the increase of stiffness is 
a precursor of fibrosis development (Ehman et al. 2010).  
A new clinical study (Talwakar et al. 2011) with 58 NAFLD patients suggests that liver 
stiffness evaluated with MR elastography was significantly higher in patients with NASH 
compared with patients with simple steatosis. Liver stiffness in patients with fibrosis (grade 
F>1) was significantly higher than that in patients with inflammation and no fibrosis. Liver 
stiffness was significantly correlated to inflammation stage and fibrosis stage. The results of 
this retrospective study support the hypothesis that NAFLD patients with inflammation but 
no fibrosis have significantly higher liver stiffness than do those with simple steatosis. Liver 
stiffness measured by means of MR elastography may be an accurate biomarker for detecting 
NASH (area under receiver operating characteristics curve, AUROC = 0.93), which suggest 
that MRE should be further investigated for its potential to stratify patients with NAFLD. MRE 
could be used to distinguish between individuals with simple steatosis and steatohepatitis. 
The presence of elevated stiffness is not specific to steatohepatitis and can be generalized at 
all the liver disease. Moreover, this technology necessitated the use of a MR device.  
6.3.2 Serologic test 
The new subject of biomarkers development is to differentiate NAFLD phenotypes and to 
detect liver injuries (ballooning, degeneration, necrosis…) to target therapies. Several tools 
have been studied: biomarkers of oxidative stress, inflammation and hepatocytes apoptosis.  
The most commonly used screening modality, the ALT, typically fluctuates in NAFLD and 
is normal in more than two-thirds of NASH patients at any given time (Wieckowska et al. 
2007). For the identification of at least 5% steatosis, Poynard et al.  reported that an ALT> 50 
IU/L had a sensitivity and specificity of only 72% and 62% respectively (AUROC , 0.61) 
(Poynard et al, 2005). 
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Several studies explored the correlation between TBARS (thibarbituric acid-reacting 
substance) and steatosis (Chalasani, 2002) (Bonnefont, 2006) but there was no significant 
correlation. Additional studies are necessary before use in clinical context. 
A new approach is the recognition of hepatocyte apoptosis. The first study correlated plasma 
CK-18 (cytokeratin-18) with NASH, CK-18 increased in patients with NASH compared to 
simple steatosis and normal biopsies (Wieckowska et al, 2006). This first study was completed 
recently by a cohort of 319 patients with biopsy proven NAFLD. CK-18 fragments were 
markedly increased in patients with NASH as compared to not NASH and borderline 
diagnosis (Median (Q25, Q75): 335 (196, 511), 194 (151, 270), 200 (148, 284), respectively; P < 
0.001). On multivariable regression analysis, CK-18 fragments remained an independent 
predictor of NASH after adjusting for variables associated with CK-18 fragments or NASH on 
the univariate analysis (fibrosis, ALT, AST, age, biopsy length). AUROC curve for NASH 
diagnosis was estimated to be 0.83 (0.75-0.91), (Feldstein et al., 2009). The same biomarker was 
studied in a prospective longitudinal study with 52 patients NAFLD, with repeated biopsies at 
month 36. Serum cytokeratin-18 fragment level correlated well with NAS both at baseline and 
month 36. The change in NAS had moderate correlation with change in serum cytokeratin-18 
fragment levels (r=0.51, p<0.001). Patients with increased NAS at month 36 had greater 
increase in serum cytokeratin-18 fragment levels (Wong et al, 2010).   
Most studies would suggest that combinations of biomarkers have the highest predictive 
utility.  
6.3.3 Composite serum markers 
Several blood tests have been proposed to diagnose liver fibrosis. Some tests are simple, like 
the aspartate aminotransferase to platelet ratio index (APRI). Others are more complex, 
constructed as algorithms (regression score) like the FibroMeter (Cales et al. 2009). Most of 
them have been developed in chronic hepatitis C or in miscellaneous causes. 
6.3.3.1 Steatosis 
Bedogni et al. CITER developed the Fatty Liver Index (FLI) by evaluating a cohort from the 
Dionysos Nutrition & Liver Study. A total of 224 subjects with suspected liver disease 
(excluding hepatitis B and C) were selected and matched with 287 subjects without 
suspected liver disease. After serial analysis, four predictors (triglycerides, BMI, gamma-
glutamyl transpeptidase (GGT) and waist circumference) were entered into a model to 
generate the FLI. The authors reported that an FLI<30 could be used to rule out and >60 to 
rule in hepatic steatosis. A limitation of this study is that the diagnosis of fatty liver was 
based on ultrasonography. 
In the same way, Poynard et al. (2009) recently reported a combination of markers for 
steatosis referred to as the SteatoTest (BioPredictive, France) This proprietary index 
combines age, gender, body mass index, cholesterol, triglycerides, glucose, ALT, GGT, 
bilirubin, haptoglobin, alpha-2-macroglobulin, and apolipoprotein A1 in a logistic 
regression formula. For the prediction of steatosis ≥ 5%, the SteatoTest value had an AUROC  
of 0.80 in a cohort of 811 patients with NAFLD, HCV and HBV, alcoholic liver disease. 
Nevertheless, a substantial overlap between grades of steatosis will likely limit its 
widespread use; Moreover, this algorithm has yet to be externally validated. The SteatoTest 
(range [0-1]) was 0.14 in blood donors, 0.26 in patients without steatosis; 0.43 with [1-5%] 
steatosis, 0.62 with 5-33% steatosis, 0.70 with 34-66 % steatosis and 0.75 with > 66 % steatosis 
(Poynard et al. 2005). 
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 Recently, Poynard and its colleaues (Poynard et al 2009)have developed a new algorithm 
called ‘Nashtest’ as a biomarker of inflammation. This proprietary tool includes the 
components of the SteatoTest in addition to AST, ALT, total bilirubin, height anf weight. In 
a study that included 257 patients with NAFLD who underwent liver biopsy, this panel was 
71% sensitive and 94% specific for the diagnosis of NASH versus no NASH  according to the 
NAFLD Activity Score. The AUROC was 0.75 (95% CI 0.67-0.82). As this index has not yet 
been externally validated, additional study is necessary prior its utilisation.  
6.3.3.3 Fibrosis 
A variety of blood tests exist to detect the NAFLD to NASH transition. For example, the 
NAFLD score was developed by Angulo to accurately separate patients with NAFLD with 
and without advanced fibrosis, rendering liver biopsy for identification of advanced fibrosis 
unnecessary in a substantial proportion of patients. This score was developed during a 
study on 733 patients (480 construction of the data basis, and 253 to validate, with NAFLD 
confirmed by biopsy). The NAFLD score is based on composed of routinely measured and 
easily available clinical and laboratory variables. The exact formula combines age, 
hyperglycaemia, body mass index (BMI), platelets, albumin, AST/ALT). In this study, the 
lower cutoff point was particularly accurate in ruling out the presence of advanced fibrosis; 
the NPV was 93% and 88% in the estimation and validation groups, respectively, and 
ranged from 87% to 98% for the prevalence of advanced fibrosis of 5% to 50%. Among these 
733 patients, 439 (60%) had a negative diagnosis of advanced fibrosis, and thus a liver 
biopsy would have been avoided by applying the NAFLD fibrosis score; of these 439, 400 
(91%) indeed had stage 0-2 fibrosis; (Angulo, 2007) However, this test was designed for 
severe fibrosis whereas most tests have been designed for significant fibrosis and usually for 
chronic hepatitis C. 
Cales and its colleagues developed a regression score specifically designed to NAFLD 
patients called Fibrometer NAFLD (Cales et al. 2009). A study on 235 patients compared 
blood tests performance (NFSA (NAFLD Score of Angulo Fibrometer, Fibrometer NAFLD 
and APRI) and biopsy results. The score combines glucose, AST, ferritin, platelet, ALT, body 
weight and age. Results gave 90% negative (NPV) and positive (PPV) predictive values for 
significant fibrosis, when values were, respectively: FibroMeter: ≤0.611 and ≥0.715, NFSA: ≤ 
0.227 and ≥0.514, APRI: ≤0.454 and ≥0.918. The ensuing proportion of patients with reliable 
diagnosis was: FibroMeter: 97.4%, NFSA: 86.8% (p < 10-3 vs FibroMeter), APRI: 80.0% (p < 
10-3). This study thus provided an independent external validation of NFSA for significant 
fibrosis in a large series and for severe fibrosis. Cales and its colleagues observed a similar 
performance for significant fibrosis of APRI AUROC compared to the original publication in 
chronic viral hepatitis C. APRI AUROC was significantly inferior to that of FibroMeter and 
NFSA for the three diagnostic targets (except with NFSA for significant fibrosis). 
All these composite serum markers are very easy to use and are able to give a first indication 
to the physician. But some of them are not free (Fibrometer NashTest and Steatotest for 
exemple) and need more external clinical validations.  
6.3.4 Fibroscan
®
 and CAP (Controlled Attenuation Parameter) 
Fibroscan® (Echosens, Paris, France) is an ultrasound-based vibration-controlled transient 
elastography (VCTE™) device used to assess liver elasticity related to liver fibrosis (Sandrin 
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et al. 2003). Liver stiffness is expressed in kPa.  Fibroscan® shows good results for the 
detection of significant fibrosis and for the diagnosis of cirrhosis in hepatitis C virus (HCV) 
(Ziol et al. 2005), hepatitis B virus (HBV) (Marcellin et al. 2009), biliary liver disease 
(Corpechot  et al. 2006), alcoholic liver disease (ALD) (Nahon et al. 2008) and NAFLD (Wong 
et al. 2010). 
Fibroscan® has high degree of accuracy and reproducibility in predicting bridging fibrosis 
and cirrhosis in patients with viral hepatitis (Fraquelli 2007, Wong 2008). Two independent 
studies of 94 (Yoneda 2007) and 120 (Tamano 2007) NAFLD patients respectively concluded 
that VCTETM is a non-invasive and useful method to screen possible NASH patients, who 
need liver biopsy, from NAFLD populations. No correlation between stiffness values and 
steatosis was finded. Moreover, these results are confirmed later by Wong and their 
colleagues (Wong, 2010) who evaluated the accuracy of VCTETM and biochemical tests for 
the diagnosis of fibrosis and cirrhosis in a large cohort of 246 NAFLD patients. They wanted 
to determine if liver stiffness was altered by hepatic steatosis, inflammation, and obesity. 
The results demonstrated the usefulness of VCTETM to quantify fibrosis: AUROC of VCTETM 
for the detection of F3 fibrosis or higher and cirrhosis was 0.93 and 0.95, respectively, and 
was significantly higher than that of the aspartate aminotransferase–to–alanine 
aminotransferase ratio, aspartate aminotransferase–to–platelet ratio index, FIB-4, BARD, and 
NAFLD fibrosis scores (AUROC ranged from 0.62 to 0.81, P<0.05 for all comparisons). At a 
cutoff value of 7.9 kPa, the sensitivity, specificity, and positive and negative predictive 
values for F3 or greater disease were 91%, 75%, 52%, and 97%, respectively. Liver stiffness 
was not affected by hepatic steatosis, necroinflammation, or body mass index. Discordance 
of at least two stages between transient elastography and histology was observed in 33 
(13.4%) patient but by multivariate analysis, liver biopsy length less than 20 mm and F0-2 
disease were associated with this discordance. Because of high negative predictive value 
and modest positive predictive value, this study concluded positively for the use of VCTETM 
as a screening test to exclude advanced fibrosis. In summary, Wong and colleagues have 
provided valuable data regarding the use of VCTETM in patients with NAFLD. Adam et al. 
underlined that the strength of Fibroscan® appears to be for excluding advanced fibrosis and 
cirrhosis; however, according to Adam, there are a number of issues that need to be clarified 
before it is routinely used in the clinical setting: cut-off values, utility in obese and morbidly 
obese populations which seem to require further validation of the dedicated obese probe 
(called XL probe). Nevertheless de Ledinghen et al. (2010) and Rust and al. (20110) have 
demonstrated VCTETM using the XL probe for obese patients can be performed with 
comparable diagnostic accuracy to the standard probe and enables the examination of 
significantly more obese patients.  
So, VCTETM based on Fibroscan® is a promising tool to quantify fibrosis but not steatosis. It’s 
why Sasso and al. (Echosens, France) had developed a new parameter called Controlled 
Attenuation Parameter (CAP) based on ultrasound attenuation. This parameter can be 
assessed simultaneously and on the same device Fibroscan® than the liver stiffness. 
Knowing that fat affects ultrasound propagation, this novel attenuation parameter is based 
on the ultrasonic properties of the radiofrequency back-propagated signals acquired by the 
Fibroscan®. It is called controlled attenuation parameter (CAP) because it was devised to 
specifically target the liver. This control is performed by a sophisticated guidance process 
based on VCTETM. Therefore, CAP can be assessed by an operator who does not have any 
ultrasound imaging skills. Furthermore, CAP has been designed to be immediate, 
reproducible and operator and machine-independent.  Performance of the CAP was then 
www.intechopen.com
 
Metabolic Steatosis & Fibrosis: Review of the Non-Invasive Tools for Diagnosis and Screening 
 
53 
appraised on 115 patients, taking the histological grade of steatosis as reference. CAP was 
significantly correlated to steatosis (Spearman ρ=0.81, p<10-16). AUROC was equal to 0.91 
and 0.95 for the detection of more than 10% and 33% of steatosis, respectively. Furthermore, 
results show that CAP can efficiently separate several steatosis grades. These results were 
confirmed by a resptropsective study an 112 patients with multiple aetiologies (HBV, HCV, 
NAFLD/ALD) (De Ledinghen et al. 2011). These promising results suggest that CAP is a 
noninvasive, immediate, objective and efficient method to detect and quantify steatosis. This 
parameter is available on Fibroscan®, is calculated during the same acquisition than the 
stiffness and than gives a steatosis evaluation in the same region of interest used for the 
stiffness (figure 2). Future clinical evaluations on NAFLD and NASH patients will be useful 
to evaluate the diagnosis performance of these 2 combined non-invasive tools and the ability 
to detect transition between simple steatosis and steatohepatitis.  
 
 
Fig. 2. Fibroscan® assess fibrosis and steatosis. 
6.3.5 Discussion 
According to Myers and his colleagues, the ideal non invasive tool includes 3 major goals: to 
diagnose NAFLD, to differentiate simple NAFLD from NASH, to determine the severity of 
fibrosis (Myers et al. 2009). Moreover, this ideal non invasive tool shall be: 
• Liver specific : true for MRI, MRS, composite serum markers, serologic tests, Fibroscan® 
(stiffness and CAP) 
• Able to detect simple steatosis : true for ultrasound (> 33%), CT, MRI, MRS, Fibroscan® 
(CAP) 
• Able to identify simple steatosis from NASH: true for composite serum markers (shall be 
evaluated), Fibroscan (stiffness and CAP, shall be evaluated) 
• sensitive enough to distinguish individual stages of fibrosis: true for serologic tests, 
composite serum markers, MRE, Fibroscan (stiffness) 
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• easy to perform and acceptable for patients and physicians: true for all non-invasive tools 
described except for CT scan cannot be repeated(ionizing) 
• Inexpensive/examination: true for ultrasound, serologic tests, composite serum markers, 
Fibroscan® 
• Reproducible: true for CT, MRI, MRS, serologic tests (shall be evaluated), composite 
serum markers, Fibroscan® 
• Responsive to change in disease (steatosis + fibrosis): true for composite serum markers 
(shall be evaluated), Fibroscan® (stiffness and CAP, shall be evaluated) 
At present only biopsy achieves most of these goals but the combination of Fibroscan® 
(stiffness and CAP) added with a blood marker could be a promising non invasive tool to 
avoid biopsy in many cases. It will be a good, simple solution, non expensive, reproducible, 
easy to use and very well accepted by the patients.  
7. Conclusion  
We have seen that NAFLD and NASH diseases are an increasing prevalence in future. The 
symptoms are very dangerous because of a silent, slow evolution. At present, the gold 
standard for the diagnosis of nonalcoholic steatohepatitis is liver biopsy; however, liver 
biopsy is not performed in a significant number of cases and in the absence of more-accurate 
imaging technologies and serum markers, the diagnosis is frequently one of exclusion. Due 
to the many potential errors due to sampling, inter/interobeserver variability, biopsy is the 
“Best” not the “Gold “ standard (Bedossa & Carrat 2009) in spite of its limitations. There is 
also urgent need for effective and easy-to-use non-invasive methods to assess the severity of 
liver disease in NAFLD: while simple steatosis has a benign hepatological prognosis and 
may be managed with measures aiming at reducing cardio-metabolic risk, NASH may 
progress to end-stage liver disease and requires early hepatological referral for experimental 
treatment and tight follow-up. Then, the most important clinical point is to detect the 
transition between benign steatosis, NALD, and NASH and to be able to assess steatosis, 
fibrosis and inflammation. Many noninvasive tests exist to quantify either fibrosis or 
steatosis but few diagnose these two. Nevertheless, new technologies appear like blood 
markers, serologic tests, specific imaging device (MRE) or Fibroscan® device with CAP to 
improve the diagnosis of NAFLD and/or NASH. It is hoped that improved imaging 
techniques and the discovery of serum biomarkers, as well as the development of clinical 
algorithms, will enable a more accurate diagnosis of NASH without the need for a liver 
biopsy. 
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